Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30641196 | 1.00 | MAPT (0.42) | MAPTSMN1; SMN2NOS1CYP1A2TDP1 | |
| SCHEMBL31179151 | 0.77 | PTPN6 (0.36) | NOS1CYP1A2TDO2IDO1 | |
| SCHEMBL27229424 | 0.77 | PTPN6 (0.36) | NOS1CYP1A2TDO2IDO1 | |
| SCHEMBL3606434 | 0.76 | NOS1 (0.53) | MAPTSMN1; SMN2NOS1CYP1A2TDP1 | |
| SCHEMBL27331407 | 0.76 | TDO2 (0.37) | MAPTSMN1; SMN2NOS1CYP1A2TDP1 | |
| SCHEMBL30850926 | 0.76 | TDO2 (0.37) | MAPTSMN1; SMN2NOS1CYP1A2TDP1 | |
| SCHEMBL14718665 | 0.76 | PIM3 (0.50) | MAPTSMN1; SMN2NOS1CYP3A4PIM3 | |
| SCHEMBL27216864 | 0.76 | NOS1 (0.49) | MAPTSMN1; SMN2NOS1CYP1A2TDP1 | |
| SCHEMBL12282300 | 0.73 | NOS1 (0.53) | MAPTSMN1; SMN2NOS1CYP1A2TDP1 | |
| SCHEMBL31217480 | 0.73 | MAPT (0.49) | MAPTSMN1; SMN2NOS1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| CN-119894872-A | Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof | 修复治疗公司 | 2025-04-25 | — | — | CN | disclosed |
| US-11492354-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210002288-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-01-07 | — | — | US | disclosed |
| US-20210002288-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-01-07 | — | — | US | disclosed |
| US-10752635-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752635-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2019164847-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190256520-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-08-22 | — | — | US | disclosed |
| US-20190256520-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | MAPT 269/4885SMN1; SMN2 1959/4885NOS1 4253/4885 |
| US-20210002288-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | PDXK, PPIP5K2, PCK1 | MAPT 3880/4885SMN1; SMN2 4471/4885NOS1 2853/4885 |
| US-10752635-B2 | Indazole compounds and uses thereof | PDXK, PPIP5K2, PCK1 | MAPT 3880/4885SMN1; SMN2 4471/4885NOS1 2853/4885 |
| US-20190256520-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | PDXK, PPIP5K2, PCK1 | MAPT 3880/4885SMN1; SMN2 4471/4885NOS1 2853/4885 |
| US-11492354-B2 | Indazole compounds and uses thereof | PDXK, PPIP5K2, PCK1 | MAPT 3880/4885SMN1; SMN2 4471/4885NOS1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.